Merck’s (NYSE:MRK) Gardasil is the leader in the human papillomavirus (HPV) vaccines market. HPV is a group of more than 200 related viruses, of which several are spread through direct sexual contact. HPV can cause cervical, anal, oropharyngeal, penile, vulvar, and vaginal cancer, and it is thus an important vaccine. There are only three U.S. FDA approved vaccines ~ Gardasil, Gardasil 9, and GlaxoSmithKline’s Cerverix ~ for HPV. Merck’s Gardasil is the leader with sales of over $3 billion in 2018. You can view our interactive dashboard analysis ~ How Big Is Merck In the Human Papillomavirus (HPV) Vaccines Market? ~ for more details. In addition, you can see more healthcare companies data here.
Merck’s Gardasil And GlaxoSmithKline’s Cerverix Are The Only Approved Vaccines For HPV.
- Merck’s Gardasil sales grew from $1.7 billion in 2014 to $3.2 billion in 2018.
- GSK’s Cerverix sales declined from $194 million in 2014 to $184 million in 2018.
- The difference in sales of these two drugs can be attributed to the addressable HPVs.
- Cervarix blocks HPV 16 and 18, while Gardasil protects against HPV 6, 11, 16 and 18.
- Note that HPV 6 and 11 cause most cases of genital warts.
Gardasil Claims The Lion’s Share In HPV Vaccines Market
- Combined sales of HPV vaccines grew from $1.9 billion in 2014 to $3.3 billion in 2018.
- Gardasil’s share increased from 90% to 93% during the same period.
- Gardasil’s share could increase slightly in the coming years, given there is no alternative.
- Gardasil sales jumped from $2.3 billion in 2017 to $3.2 billion in 2018, primarily due to its launch in China.
- We expect the growth to continue in the near term, led by an increased demand, amid higher vaccination rate.
Both Cerverix And Gardasil Are Protected From Biosimilar Competition Till 2028 In The U.S.
- Cerverix Loss of Exclusivity: 2028 (US) | 2022 (EU)
- Gardasil Loss of Exclusivity: 2028 (US) | 2021 (EU)
Gardasil Is A Blockbuster Drug For Merck, And It Accounts For Over 7% of The Company’s Total Sales
- Merck’s total sales have hovered in the range of $40-42 billion over the last few years.
- Gardasil sales have grown during the same period, resulting in higher contribution to the company’s top line.
- Gardasil’s contribution to Merck’s overall sales has increased from 4% in 2014 to over 7% in 2018.
What’s behind Trefis? See How it’s Powering New Collaboration and What-Ifs
For CFOs and Finance Teams | Product, R&D, and Marketing Teams
All Trefis Data
Like our charts? Explore example interactive dashboards and create your own.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.